Open access
Open access
Powered by Google Translator Translator

Chest Medicine

Systematic Review: Are there ways to improve stop-smoking treatment in primary care to help more people quit smoking?

30 Nov, 2021 | 10:03h | UTC

Summary: Are there ways to improve stop-smoking treatment in primary care to help more people to quit smoking? – Cochrane Library

Original Study: Strategies to improve smoking cessation rates in primary care – Cochrane Library

 

WHO Technical Brief and Priority Actions: Enhancing Readiness for Omicron.

30 Nov, 2021 | 08:46h | UTC

Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States – World Health Organization

Commentaries:

The World Health Organization warns of very high risk posed by the omicron variant – NPR

Omicron Covid variant poses very high global risk, says WHO – The Guardian

See also the latest articles on the subject:

Statement On Omicron Variant – Infectious Diseases Society of America

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear – The BMJ

Helen Salisbury: Omicron—panic mongering or appropriate caution? – The BMJ

The Omicron variant underscores the global stakes of Covid-19 vaccine inequity – STAT

EXPLAINER: What we know and don’t know about omicron variant – Associated Press

Omicron: How do you detect it? – BBC

Are new COVID variants like Omicron linked to low vaccine coverage? Here’s what the science says – The Conversation

Omicron: why the WHO designated it a variant of concern – The Conversation

It looks like Omicron causes milder illness – is this how COVID becomes endemic? – The Conversation

As Omicron spreads, studies suggest that travel bans alone don’t do much good – NPR

 

Preliminary RCT found prostacyclin may improve outcomes in mechanically ventilated patients with COVID-19 and severe endotheliopathy.

30 Nov, 2021 | 08:42h | UTC

Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial – American Journal of Respiratory and Critical Care Medicine

News release: Well-known drug could help the most severely affected COVID-19 patients in intensive-care departments – by University of Copenhagen

 

Commentary from the author on Twitter (thread – click for more)

 

ESCMID COVID-19 Living guidelines: drug treatment and clinical management.

30 Nov, 2021 | 08:40h | UTC

ESCMID COVID-19 Living guidelines: drug treatment and clinical management – Clinical Microbiology and Infection

 

WHO Update on Omicron + Several Articles on the Subject.

28 Nov, 2021 | 21:38h | UTC

Update on Omicron – World Health Organization

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern – World Health Organization

See also:

Omicron COVID-19 variant: Africa CDC statement

Expert reaction to B.1.1.529 variant situation in South Africa; and UK travel restrictions in response – Science Media Centre

Threat Assessment Brief: Implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 variant of concern (Omicron) for the EU/EEA – European Centre for Disease Prevention and Control

‘Patience is crucial’: Why we won’t know for weeks how dangerous Omicron is – Science

Scientists rapidly identified the Omicron variant. But firm answers about its impact could take weeks – STAT

New Covid variant: Will new measures against Omicron work? – BBC

Vaccine inequity and hesitancy made the Omicron variant more likely, scientists say – CNN

Travel bans aren’t the answer to stopping new COVID variant Omicron – The Conversation

Scientists sharing Omicron data were heroic. Let’s ensure they don’t regret it – The Guardian

The Omicron variant reveals the true global danger of ‘vaccine apartheid’ – The Guardian

We Know Almost Nothing About the Omicron Variant – The Atlantic

Covid: New Omicron variant not a disaster, says Sage scientist – BBC

New Covid variant: Will new measures against Omicron work? – BBC

World is put on high alert over the Omicron coronavirus variant – CNN

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant – Moderna

Omicron is the new COVID kid on the block: five steps to avoid, ten to take immediately – The Conversation

What’s known and unknown about Omicron, the coronavirus variant identified in South Africa – STAT

The new variant is worrying – but it doesn’t change how we tackle Covid – The Guardian

Omicron: everything you need to know about new Covid variant – The Guardian

Omicron variant unlikely to reboot Covid in UK, expert says – The Guardian

UK detects Omicron cases, as more countries eye new COVID-19 variant – CIDRAP

New COVID variant alarms researchers, triggers travel bans – CIDRAP

The omicron variant spreads across Europe as new travel bans take effect – NPR

What to know about omicron, the new COVID variant – NPR

What we know about the Omicron variant – CNN

The new Omicron variant is a pandemic gut check – CNN

Newly discovered Covid-19 variant B.1.1.529 is ‘red flag’ but US needs to learn more, Fauci says – CNN

Omicron, a new Covid-19 variant with high number of mutations, sparks travel bans and worries scientists – CNN

What to know about the omicron variant of the coronavirus – The Washington Post

 

Commentary on Twitter (thread – click for more)

 

M-A: Observational data on the effectiveness of COVID-19 vaccines.

30 Nov, 2021 | 08:37h | UTC

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis – International Journal of Infectious Diseases

 

Omicron Variant: Videos with opinions on the subject.

28 Nov, 2021 | 21:33h | UTC

 

Too early to tell, but preliminary information from doctors in South Africa suggests the new Covid variant Omicron may be associated with less severe disease.

28 Nov, 2021 | 21:35h | UTC

 

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

28 Nov, 2021 | 21:30h | UTC

News Release: Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Commentary: New data, analyses take some of the shine off Merck’s Covid pill – STAT

Related:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Commentaries on Twitter

 

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

28 Nov, 2021 | 21:22h | UTC

Executive Summary: Screening for Lung Cancer: Chest Guideline and Expert Panel Report

Full Guideline: Screening for Lung Cancer: CHEST Guideline and Expert Panel Report

News Release: CHEST releases expert guidelines for lung cancer screening – Elsevier

Related:

USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk

Meta-analysis: Lung cancer screening using low-dose computed tomography reduces lung cancer–specific mortality, albeit with a tradeoff of likely overdiagnosis

 

Commentary on Twitter

 

ATS Guideline: Use of fractional exhaled nitric oxide to guide the treatment of asthma.

28 Nov, 2021 | 21:20h | UTC

Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline – American Journal of Respiratory and Critical Care Medicine

News Release: New Clinical Practice Guideline on Fractional Exhaled Nitric Oxide (FeNO) to Help Guide Asthma Treatment – American Thoracic Society

 

Phase II RCT: Efficacy and safety of Itepekimab in patients with moderate-to-severe asthma.

26 Nov, 2021 | 09:46h | UTC

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentaries on Twitter

 

Heavily mutated coronavirus variant puts scientists on alert – “Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines’ effectiveness”.

26 Nov, 2021 | 08:42h | UTC

Heavily mutated coronavirus variant puts scientists on alert – Nature

See also:

Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern – BBC

WHO calls special meeting to discuss new Covid variant found in South Africa with ‘a large number of mutations’ – CNBC

New COVID-19 Variant With Multiple Concerning Mutations Identified in Southern Africa – Health Policy Watch

Scientists warn of new Covid variant with high number of mutations – The Guardian

South Africa detects new COVID variant with many mutations – MedicalXpress

 

Related commentary on Twitter (thread – click for more)

 

Review: Prevention and management of thrombosis in hospitalized patients with COVID-19 pneumonia.

26 Nov, 2021 | 08:44h | UTC

Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia – The Lancet Respiratory Medicine

 

M-A: Comparing the clinical efficacy of COVID-19 vaccines.

26 Nov, 2021 | 08:37h | UTC

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis – Scientific Reports

 

[Preprint] Serological responses to COVID-19 booster vaccine in England.

26 Nov, 2021 | 08:34h | UTC

Serological responses to COVID-19 booster vaccine in England – medRxiv

 

Commentary from the author on Twitter (thread – click for more)

 

COVID-19 reinfection: the role of natural immunity, vaccines, and variants.

25 Nov, 2021 | 10:45h | UTC

COVID-19 reinfection: the role of natural immunity, vaccines, and variants – Journal of Community Hospital Internal Medicine Perspectives

Related: [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

 

A population-based cohort study in Qatar showed reinfections had 90% lower odds of resulting in hospitalization or death than primary infections.

25 Nov, 2021 | 10:46h | UTC

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections – New England Journal of Medicine

Related: [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

 

Promises and challenges of personalized medicine to guide ARDS therapy.

25 Nov, 2021 | 10:25h | UTC

Promises and challenges of personalized medicine to guide ARDS therapy – Critical Care

 

Systematic Review: Macrolides versus placebo for chronic asthma.

25 Nov, 2021 | 10:14h | UTC

Macrolides versus placebo for chronic asthma – Cochrane Library

 

Commentary on Twitter

 

Basics of extracorporeal membrane oxygenation.

25 Nov, 2021 | 10:09h | UTC

Basics of Extracorporeal Membrane Oxygenation – Surgical Clinics of North America

 

Review: Noninvasive ventilation and oxygenation strategies.

25 Nov, 2021 | 10:08h | UTC

Noninvasive Ventilation and Oxygenation Strategies – Surgical Clinics of North America

 

Review: COVID-19-associated Invasive Fungal Infection.

24 Nov, 2021 | 08:48h | UTC

COVID-19-associated Invasive Fungal Infection – Open Forum Infectious Diseases

Related:

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.

M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.

Consensus Guideline: Defining and managing COVID-19-associated pulmonary aspergillosis

Bacterial and fungal superinfections in critically ill patients with COVID-19

Invasive Fungal Disease complicating COVID-19: when it rains it pours

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients

 

Commentary on Twitter

 

We expected people with asthma to fare worse during COVID. Turns out they’ve had a break.

24 Nov, 2021 | 08:44h | UTC

We expected people with asthma to fare worse during COVID. Turns out they’ve had a break – The Conversation

 

A prospective cohort study showed a 3.1% risk for recurrent venous thromboembolism at 90 days in patients with subsegmental pulmonary embolism managed without anticoagulation.

24 Nov, 2021 | 08:31h | UTC

Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation: A Multicenter Prospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.